Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Doseology Sciences Inc.

Healthcare US DOSEF

0.1121USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

0.130.13
LowHigh

52 Week Range

0.051.50
LowHigh

Fundamentals

  • Previous Close 0.11
  • Market Cap3.93M
  • Volume5000
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.44779M -0.33985M -1.78154M -1.93932M -1.62656M
Minority interest - - - - -
Net income -0.44779M -0.33985M -1.78154M -1.93932M -1.62656M
Selling general administrative 0.43M 0.35M 0.76M 1.28M 1.19M
Selling and marketing expenses - - - 0.19M 0.17M
Gross profit 0.02M 0.07M 0.04M -0.14838M 0.00000M
Reconciled depreciation 0.00000M 0.02M 0.07M 0.14M 0.09M
Ebit - - - -1.80981M -1.56426M
Ebitda - - - -1.67027M -1.47142M
Depreciation and amortization - - - 0.14M 0.09M
Non operating income net other - - - - -
Operating income -0.47161M -0.37763M -0.83217M -1.80981M -1.56426M
Other operating expenses - - - 1.83M 1.57M
Interest expense - 0.00000M 0.04M 0.08M 0.07M
Tax provision - - - - -
Interest income 0.02M 0.03M 0.07M 0.00684M 0.00302M
Net interest income 0.02M 0.03M 0.03M -0.06894M -0.06528M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 0.08M 0.07M
Total revenue 0.04M 0.10M 0.04M 0.02M 0.00000M
Total operating expenses 0.51M 0.48M 0.88M 1.67M 1.57M
Cost of revenue 0.02M 0.03M 0.00180M 0.16M 0.00000M
Total other income expense net - 0.00850M -0.97828M -0.05374M 0.00600M
Discontinued operations - - - - -
Net income from continuing ops -0.44779M -0.33985M -1.78154M -1.93932M -1.62656M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 1.49M 1.10M 1.40M 3.87M 5.99M
Intangible assets - - - 0.01M 0.08M
Earning assets - - - - -
Other current assets - - - 1.00M -0.00018M
Total liab 0.09M 0.08M 0.10M 0.87M 3.41M
Total stockholder equity 1.40M 1.02M 1.30M 3.00M 2.58M
Deferred long term liab - - - - -
Other current liab - - - 0.03M 2.67M
Common stock - - - 6.71M 4.53M
Capital stock 7.50M 6.75M 6.71M 6.71M 4.53M
Retained earnings -6.56669M -6.11890M -5.77905M -3.99751M -2.05819M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 1.43M 1.06M 1.30M 1.87M 3.73M
Cash and equivalents - - - - -
Total current liabilities 0.09M 0.08M 0.09M 0.22M 2.75M
Current deferred revenue - - - - 0.36M
Net debt - - - -1.12832M -3.04598M
Short term debt - - - 0.09M 0.03M
Short long term debt - - - - -
Short long term debt total - - - 0.75M 0.69M
Other stockholder equity - - - - -
Property plant equipment - - - - -
Total current assets 1.49M 1.10M 1.34M 2.97M 5.00M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.02M 0.00230M 0.00252M 0.09M 0.04M
Long term debt - - - - -
Inventory 0.02M 0.04M 0.00859M 0.01M 0.13M
Accounts payable 0.04M 0.05M 0.02M 0.09M 0.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - 0.28M 0.11M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.06M 0.90M 0.99M
Capital lease obligations - 0.00000M 0.05M 0.75M 0.69M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - - 0.00000M -0.00788M -0.02605M
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings 0.00000M -0.00614M - - -
Total cash from financing activities 0.71M -0.00614M -0.09188M -0.14008M 5.79M
Change to operating activities - - - - -
Net income -0.44779M -0.33985M -1.78154M -1.93932M -1.62656M
Change in cash 0.37M -0.24126M -0.57294M -1.85911M 3.39M
Begin period cash flow 1.06M 1.30M 1.87M 3.73M 0.34M
End period cash flow 1.43M 1.06M 1.30M 1.87M 3.73M
Total cash from operating activities -0.34224M -0.23512M -0.48105M -1.71115M -2.36816M
Issuance of capital stock 0.73M 0.00000M - 0.00000M 6.22M
Depreciation 0.00000M 0.02M 0.07M 0.14M 0.09M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.02M -0.03111M 0.00180M -0.03862M -0.12924M
Change to account receivables - - - - -
Sale purchase of stock - - - 0.00000M -0.27500M
Other cashflows from financing activities - - - -0.01978M -0.09973M
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00788M 0.17M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.00849M 0.03M 0.14M -0.28427M -0.91656M
Stock based compensation 0.10M 0.02M 0.08M 0.09M 0.02M
Other non cash items 0.02M 0.03M 0.75M 0.29M 0.06M
Free cash flow -0.34224M -0.23512M -0.48105M -1.71903M -2.53830M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DOSEF
Doseology Sciences Inc.		 - -% 0.11 - - 51.54 3.85 53.50 0.13
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distributors. The company was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.

Doseology Sciences Inc.

9-3151 Lakeshore Road, Kelowna, BC, Canada, V1W 3S9

Key Executives

Name Title Year Born
Mr. Ralph O. Olson Interim CEO & Chairman 1958
Mr. Peter Geh Chief Financial Officer NA
Ms. Harbir Thoor C.A., CPA Director & Independent Audit Chair NA
Mr. Christopher Jackson CEO & Director 1970
Mr. Timothy Corkum President & COO 1973
Mr. Daniel Vice Co-Founder & Independent Director NA
Mr. Christopher P. Cherry Chief Financial Officer NA
Mr. Lawrence Latowsky Executive Chairman of the Board 1961
Ms. Lindsay Hamelin Corporate Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.